Endo International plc – (ENDP) Position Increased by Alps Advisors Inc.

Alps Advisors Inc. boosted its position in shares of Endo International plc – (NASDAQ:ENDP) (TSE:ENL) by 22.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 307,839 shares of the company’s stock after purchasing an additional 57,328 shares during the quarter. Alps Advisors Inc.’s holdings in Endo International were worth $2,386,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Diamond Hill Capital Management Inc. grew its position in Endo International by 46.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock valued at $6,138,000 after purchasing an additional 228,426 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in Endo International by 18.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company’s stock valued at $4,447,000 after purchasing an additional 62,822 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new stake in Endo International during the 3rd quarter valued at about $293,000. Ameriprise Financial Inc. grew its position in Endo International by 4.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 581,552 shares of the company’s stock valued at $6,497,000 after purchasing an additional 27,414 shares during the last quarter. Finally, Nomura Holdings Inc. purchased a new stake in Endo International during the 2nd quarter valued at about $745,000. 92.53% of the stock is currently owned by institutional investors.

Shares of Endo International plc – (NASDAQ:ENDP) opened at $6.26 on Friday. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. The stock has a market cap of $1,440.00, a PE ratio of -0.32, a PEG ratio of 2.30 and a beta of 0.29. Endo International plc – has a 1-year low of $5.77 and a 1-year high of $14.45.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 EPS. sell-side analysts forecast that Endo International plc – will post 3.68 earnings per share for the current year.

Several analysts recently commented on ENDP shares. Mizuho reissued a “buy” rating and set a $12.00 price objective (down from $14.00) on shares of Endo International in a research report on Wednesday, January 3rd. Leerink Swann started coverage on shares of Endo International in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $12.00 price objective on the stock. Vetr raised shares of Endo International from a “buy” rating to a “strong-buy” rating and set a $8.92 price objective on the stock in a research report on Tuesday, December 26th. Cantor Fitzgerald set a $9.00 price objective on shares of Endo International and gave the company a “hold” rating in a research report on Monday, October 30th. Finally, Zacks Investment Research downgraded shares of Endo International from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Endo International currently has a consensus rating of “Hold” and an average target price of $10.54.

TRADEMARK VIOLATION WARNING: “Endo International plc – (ENDP) Position Increased by Alps Advisors Inc.” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2018/02/09/endo-international-plc-endp-position-increased-by-alps-advisors-inc.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International plc – (NASDAQ:ENDP) (TSE:ENL).

Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit